COMP <GO>
MOH vs LLY // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Molina Healthcare Inc (NYSE) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: MOH 3
— LLY 11
■ METRIC PARITY
LAST: $198.95 (+0.43%) • MKT CAP: $10.39B
options-implied-move
—
LAST: $1,373.70 (+6.63%) • MKT CAP: $1.29T
options-implied-move
6.77%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MOH VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MOH | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 13.10% | 83.64% | -70.54 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 17.20% | 32.36% | -15.16 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 11.4x | 36.4x | -25.02 | MOH | /valuation <GO> |
| Free Cash Flow Yield | -6.12% | 2.30% | -8.42 | LLY | /fcf-yield <GO> |
| Operating Margin | 1.70% | 40.21% | -38.51 | LLY | /operating-margins <GO> |
| Net Profit Margin | 1.00% | 31.90% | -30.90 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 11.70% | 45.51% | -33.81 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.34 | 9.29 | -4.95 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 9/9 | -5.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.2 | 66.6 | -20.40 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.94 | 0.51 | +0.43 | MOH | /macro-sensitivity <GO> |
| Forward P/E Multiple | 20.5x | 26.3x | -5.75 | MOH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.39B | $1.29T | -$1.28T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MOH REV | LLY REV | MOH GROSS % | LLY GROSS % | MOH FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $45.43B | $65.18B | 13.1% | 83.0% | -$636.0M | $16.81B |
| FY 2024 | $40.65B | $45.04B | 15.3% | 81.3% | $544.0M | $8.82B |
| FY 2023 | $34.07B | $34.12B | — | 79.3% | $128.8M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MOH // BETA 0.94
LLY // BETA 0.51